Evidence map›Paper›PMID 30840763›Full record

ArticleThe Journal of infectious diseases2019

Impact of Treatment Interruption on HIV Reservoirs and Lymphocyte Subsets in Individuals Who Initiated Antiretroviral Therapy During the Early Phase of Infection.

Erin D Huiting, Kathleen Gittens, J Shawn Justement, Victoria Shi, Jana Blazkova, Erika Benko, Colin Kovacs, Paul A Wender, Susan Moir, Michael C Sneller and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Erin D HuitingLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases.
Kathleen GittensCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland.
J Shawn JustementLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases.
Victoria ShiLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases.
Jana BlazkovaLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases.
Erika BenkoMaple Leaf Medical Clinic, Toronto, Canada.
Colin KovacsMaple Leaf Medical Clinic, Toronto, Canada.
Paul A WenderStanford University, California.
Susan MoirLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases.
Michael C SnellerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases.
Anthony S FauciLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases.
Tae-Wook ChunLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases.
National Institute of Allergy and Infectious Diseases · USMaple Leaf Medical Clinic · CANational Institutes of Health Clinical Center · USStanford University · US

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
Role of Viral Reservoirs in the Pathogenesis of HIV DiseaseZIAAI000851 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHUN, TAE-WOOK · 2009 to 2025
$29.3M
Role of B Lymphocytes In HIV Infection And PathogenesisZIAAI000825 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MOIR, SUSAN · 2009 to 2025
$24.5M
SYNTHETIC STUDIES RELATED TO CANCER RESEARCH/TREATMENTR01CA031845 · NCI · STANFORD UNIVERSITY · PI PAUL Anthony WENDER · 1985 to 2026
$6.9M
Synthetic Studies Related to Cancer Research/TreatmentR37CA031845 · NCI · STANFORD UNIVERSITY · PI WENDER, PAUL ANTHONY · 2006 to 2015
$4.5M
HIV latency reversal through novel, potent PKC modulatorsR01AI124743 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WENDER, PAUL ANTHONY, ZACK, JEROME A. · 2016 to 2020
$3.3M
NCI NIH HHS R01 CA031845NCI NIH HHS R37 CA031845NIAID NIH HHS P30 AI028697NIAID NIH HHS R01 AI124743
6 · The paper itself

Abstract

Therapeutic strategies for achieving sustained virologic remission are being explored in human immunodeficiency virus (HIV)-infected individuals who began antiretroviral therapy (ART) during the early phase of infection. In the evaluation of such therapies, clinical protocols should include analytical treatment interruption (ATI); however, the immunologic and virologic impact of ATI in individuals who initiated ART early has not been fully delineated. We demonstrate that ATI causes neither expansion of HIV reservoirs nor immunologic abnormalities following reinitiation of ART. Our findings support the use of ATI to determine whether sustained virologic remission has been achieved in clinical trials of individuals who initiated ART early during HIV infection.

Indexed as

Anti-Retroviral AgentsHIV-1HIV InfectionsHumansLongitudinal StudiesLymphocyte SubsetsSecondary PreventionAnti-Retroviral Agentsacute/early HIV infectionanalytical treatment interruptionantiretroviral therapyHIV reservoirs

Identifiers

PMID30840763
PMCPMC6941494
OpenAlexW2921227502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.